Peptide analogues of Sch 37137 the antifungal antibiotic have been synthesized and evaluated in vitro against Candida sp. Di-and tripeptides containing methionine, leucine, norvaline, lysine, glutamic acid and N3-(£rans-epoxysuccmamoyl)-L-2,3-diaminopropanoic acid, (EADP) were obtained. Peptides containing (d)-, and (L)-/nmy-epoxysuccinamic acid were also prepared. All of the analogues examined displayed in general higher anticandidal activity than a mixture of diastereomers of Sch 37137.
Fungal infections caused mainly by Candida albicans have increased rapidly in the last decades especially in immunocompromisedpatients such as patients with AIDS, organ transplant recipients, cancer patients undergoing chemotherapy and can cause secondary infections that are life threatening1~4). Unfortunately, antifungal drugs currently released for clinical use have not offered substantive improvements over amphotericin B, still the drug of choice for most fungal diseases5). Therefore, there is still a need for new, safer and more potent antifungal agents. Fungal cell wall biosynthesis can provide important targets for antifungal agents6). Glucosamine-6-phosphate synthase, an enzyme which enables the biosynthetic formation of glucosamine containing macromolecules of the fungal cell wall, has been proposed by us as a target for the design of antifungal agents7), Our efforts towards rational design of antifungal agents based on this approach have been focused on glucosamine-6-phosphate synthase inhibitors, AT3-(4-methoxyfumaroyl)-and JV3-iodoacetyl=L-2,3-diaminopropanoic acids and their peptide conjugates with antifungal activity8~10). Recently Schering group isolated1 1} and synthesized1 2) antibiotic Sch 371 37, i.e. iV2-L-alanyl-Af3-(D^ra«s-epoxysuccinamoyl)-L-2,3-diaminopropanoic acid. Structural similarity of this antibiotic to antibiotic A 1900913~15) (which differs from Sch 37137 by containing a double bond instead of an epoxide ring) and to 7V3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid (FMDP) derivatives9*, both being the glutamine analogs, suggests its mechanism of antifungal action by inhibition of glucosamine-6-phosphate synthase. Our previous report on Sch 3713716), showed that its diastereoisomeric mixture exhibited a high degree of activity against Candida species. This prompted us to synthesize a series of Sch 37137 analogues in order to improve their in vitro anticandidal activities and to gain information on their structure activity relationships. This report describes the synthesis and in vitro anticandidal evaluation of a series ofpeptide analogs of Sch 37137.
Chemistry
Classical reactions used in peptide chemistry were employed for the preparation of a series of analogs of Sch 37137, including synthesis of a diastereomeric mixtures as well as both enantiomers. The 2jR,3i* Chart 1. configuration of the epoxide moiety of natural Sch 37137 has been established independently by other authors12). Most of the syntheses were performed with the use of the racemic /raws-epoxysuccinic acid. Our method of synthesis was based in general on the procedure reported earlier for the preparation of Sch 37137 derivatives16).
Compounds obtained during the synthesis are summarized in Chart 1.
Treatment of 7V3-(DL-/ra^-4-ethoxyepoxysuccinyl)-L-2,3-diaminopropanoic acid (EEDP) 1 with Nhydroxy-succinimide esters17) of Boc-Nva, Boc-Met and Boc-Leu afforded the protected dipeptides 2, 3 and 4, respectively, in good yields. Dipeptide Boc-Nva-EEDP 2 after deptotection of the Boc group was coupled again using the active ester strategy with Boc-Nva, Boc-Lys(Boc) and Boc-Glu(OBzl)18) to give the protected tripeptides 6, 7 and 8. Boc-EEDP-OSu16) was reacted with norvaline to give dipeptide 10 which was reacted either with ammonia first followed by deblocking with trifluoroacetic acid to obtain the deprotected dipeptide 10a or deblocked with trifluoroacetic acid first and reacted with active ester of acids were converted into their monomethyl esters according to the procedure described earlier19) and activated with DCCand HOSuto give the active esters which were allowed to react with A^2-(^r/-butoxycarbonyl)-L-2,3-diaminopropanoic acid (Boc-A2pr)20), deblocked and coupled with protected amino acids using the earlier reported methodology to obtain the peptides 14, 16 and 18. The protected peptides after treatment with ammonia followed by acidolysis with trifluoroacetic acid gave the Sch 37137 analogs, 2a~18a (Table 1) for antifungal testing.
Results and Discussion
The in vitro activity of Sch 37137 analogs was examined against selected Candida sp. bv the broth dilution method in YNBmedium21} (agar dilution method was also applied for comparison purposes). As shownin Table 2 most of the synthesized peptides appeared to be more active than a racemic mixture of Sch 371 37 previously prepared in our laboratory16). However, among the peptides obtained, the activity changed depending on the amino acid incorporated into the peptide chain. Dipeptide with norvaline residue in the JV-terminal position was shown to be the most active peptide tested. Also lengthening of a peptide chain altered the anticandidal activity. In general, tripeptides were somewhat less potent than dipeptides. Chirality of the trans-Qpoxysuccinic acid was another factor influencing on the activity. Thus, dipeptide having D-/r«^-epoxysuccinamic acid (2R,3R isomer) showed higher activity than compound with the l-acid (approximately 20 times higher) suggesting that the d chirality is essential for antifungal activity. Accordingly, the tripeptide Lys-Nva-EADP with the (2R,3R) configuration of the epoxy acid exhibited higher activity than corresponding peptide with a racemic epoxy acid. Interestingly, peptide ll Growth was performed in the 5% solution of serum albumin in YNBmodified mediumor 1 : 1 mixture of YNBmodified medium and serum, but peptides were previously preincubated in the presence of serum proteins for 2 hours at 37°C before inoculation.
HSA-Human serum albumin, HS-Humanserum.
(EEDP-Nva) containing an ethyl ester instead of an amide group in the trans-epoxy acid moiety showed weak anticandidal activity. The most active peptide containing AT3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid (FMDP), i.e: Lys-Nva-FMDP9) was also used for comparative testing. This compound however was less active than the Sch 37137 analogues obtained in this study. The uptake of various peptides with the xacemic epoxide moiety ( (Table 4) with 5% human serum albumin and especially in complete humanresulted in the significant loss of their antifungal efficacy. It suggested the interaction of serum proteins with the peptides by an unknown mechanism which needs further investigation.
In conclusion, a series of Sch 37137 analogs have been synthesized and evaluated for in vitro anticandidal activity. These peptides are taken up into cells via peptide permeases ("portage" transport23)), followed by enzymatic hydrolysis inside the cell and intracellular generation of the enzyme inhibitor. Anticandidal activity is influenced by the length of the peptide chain, the kind of amino acid incorporated into the peptide and the chirality of the /ra«s-epoxysuccinic acid. The A/-hydroxysuccinimide esters of ]V-(terf-butoxycarbonyl)amino acids (Nva, Lys, Met, Leu and Glu(OBzl)) were prepared by the previously described method1 7). Monoethyl l-and D-frara-epoxysuccinate were prepared according to the published procedure19).
Representative synthetic route to a Sch 37137 analogue. The following compoundswere also prepared. A^2
This compoundwas prepared from Boc-Nva-OSuand compound5 according to the procedure described for the preparation of2. 0.47g (83% yield 
succinimido ester16) and L-norvaline by the procedure used to prepare 2, compound10 was obtained. 
14 was prepared from Boc-Nva-OSu and 13 as described for the preparation of 2 in 85% yield. MP General Procedure for Ammonolysisand Deprotection of Peptides The appropriate peptide 2, 3, 4, 6, 7, 9, 10, 12, 14, 16 ancL18 (1 mmol) was stirred in a cold ammonia solution (29%), 20ml for 2hours, then ammoniawas evaporated, the crude residue dissolved in 5ml of water and passed through a short column of Amberlite CG 50 (H+), washed with water, evaporated and dried over KOH,then treated with 5 ml cold trifluoroacetic acid for 2hours. The solvent was removed under reduced pressure leaving the deprotected peptides 2a, 3a, 4a, 6a, 7a, 9a, 10a, 12a, 14a, 16a and 18a.
Yields and analytical data are collected in Table 1 .
